Heart Failure
RSSArticles
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin to placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin vs. placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure
An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.
-
Sodium Restriction in Chronic, Stable Heart Failure Patients
A study of a low-sodium diet for chronic, stable heart failure patients after one year showed no difference in hard clinical outcomes, but the degree of sodium restriction was modest.
-
Sodium Restriction in Chronic, Stable Heart Failure Patients
A study of a low-sodium diet for chronic, stable heart failure patients after one year showed no difference in hard clinical outcomes, but the degree of sodium restriction was modest.
-
Searching for the Best Echo Parameter to Predict Aortic Stenosis Outcomes
In a study of two large echocardiographic databases, the authors observed maximum aortic velocity exhibits a strong linear relationship, with the risk of mortality starting at velocities of 100 cm/s, whereas calculated aortic valve area was not related to mortality until the valve area was <1.5 cm2.
-
Interatrial Shunt Device for Heart Failure Disappoints
Placement of an interatrial shunt device in patients with heart failure with preserved or mildly reduced ejection fraction did not lower the rate of heart failure events or improve health status.
-
Treatment Indication for Diabetes Drug Expanded to Include Heart Failure
FDA approves empagliflozin to help lower risk of hospitalization, death among heart failure patients.
-
Screen Older Heart Failure Patients for Transthyretin Cardiac Amyloidosis
A screening study of heart failure patients ≥ age 60 years, left ventricular ejection fraction ≥ 40%, and left ventricle wall thickness ≥ 12 mm revealed 6.3% prevalence of transthyretin cardiac amyloidosis, a highly treatable disease.
-
USPSTF Weighs in on Key Cardiology Topics
Should clinicians screen asymptomatic older patients for atrial fibrillation? What is the best treatment course for patients without cardiovascular disease risk?